A recent study has found a new experimental painkiller that may provide relief without the risks associated with traditional opioids. The drug, called SBI-810, works by blocking pain signals in the body instead of acting broadly, like opioids do.
In tests on mice, SBI-810 effectively reduced pain from various issues such as surgeries, bone fractures, and nerve injuries. Notably, it didn’t cause common side effects associated with opioids, like sedation (feeling very sleepy) or constipation.
Researchers from Duke University, who are conducting this study, believe SBI-810 could change how we treat pain. Rather than affecting multiple pathways in the body and causing addiction, this new medication targets a specific pathway responsible for pain relief. This focused approach avoids the euphoric effects that can lead to misuse.
The study, published on May 19 in the journal *Cell*, also showed that when SBI-810 is used alongside opioids, it could make those opioids work better at lower doses. This means patients could potentially need less of the opioid, reducing the risk of addiction and negative side effects over time.
Currently, SBI-810 is in early development, but researchers are planning to begin human trials soon. This development comes at a crucial time, as more than 80,000 Americans die each year due to opioid overdoses, and about one-third of the U.S. population suffers from chronic pain.
The Duke researchers hope that SBI-810 could offer a safer alternative for managing both short-term and long-term pain, especially for individuals recovering from surgery or living with conditions like diabetic nerve pain.
